A
Amalia Londono Tobon
Researcher at Yale University
Publications - 28
Citations - 286
Amalia Londono Tobon is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Mental health. The author has an hindex of 5, co-authored 16 publications receiving 135 citations. Previous affiliations of Amalia Londono Tobon include Stanford University & Brown University.
Papers
More filters
Journal ArticleDOI
Prenatal and perinatal risk factors in a twin study of autism spectrum disorders.
Wendy M Froehlich-Santino,Amalia Londono Tobon,Sue C. Cleveland,Andrea Torres,Jennifer M. Phillips,Brianne Cohen,Tiffany Torigoe,Janet Miller,Angie Fedele,Jack Collins,Karen Müller Smith,Linda Lotspeich,Lisa A. Croen,Sally J Ozonoff,Clara Lajonchere,Judith K. Grether,Ruth O'Hara,Joachim Hallmayer +17 more
TL;DR: Perinatal factors associated with respiratory distress and other markers of hypoxia appear to increase risk for autism in a subgroup of twins, and future studies examining potential gender differences and additional prenatal, perinatal and postnatal environmental factors are required.
Journal ArticleDOI
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Jennifer B. Dwyer,Angeli Landeros-Weisenberger,Jessica A. Johnson,Amalia Londono Tobon,José M. Flores,Madeeha Nasir,Kevin Couloures,Gerard Sanacora,Michael H. Bloch +8 more
TL;DR: Although intravenous ketamine has shown efficacy in adult treatment-resistant depression, it has not been shown to be effective in adolescent depression as discussed by the authors, and is associated with significant morbidity and mortality.
Journal ArticleDOI
Social Determinants of Health: the Impact of Racism on Early Childhood Mental Health
TL;DR: This article found that racism is a social determinant of health that adversely impacts infant and early childhood socioemotional, and behavioral development, and interventions to prevent and mitigate the effects of racism.
Journal ArticleDOI
Opioid Use in Pregnancy.
TL;DR: Maintenance therapy with methadone or buprenorphine remains the standard of care for pregnant women with OUD given its consistent superiority to placebo in terms of rates of illicit drug use and pregnancy outcomes.